IN8bio Inc
Research IN8bio Inc (INAB) on Bullrun: market cap USD 11.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINAB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.53M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 18.98M
- Free cash flow-USD 14.55M
Valuation Snapshot
latest market cap is USD 11.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 19.44M | -USD 12.71M | n/a | -4.44 | USD 27.31M | USD 2.78M | USD 27.56M |
| FY2024 | USD 0 | -USD 30.44M | -USD 24.34M | n/a | -17.05 | USD 11.39M | USD 5.03M | USD 14.48M |
| FY2023 | n/a | -USD 30.01M | -USD 23.88M | n/a | -1 | USD 21.54M | USD 4.89M | USD 24.94M |
| FY2022 | n/a | -USD 28.52M | n/a | n/a | -1.36 | USD 18.43M | USD 2.01M | USD 22.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 11.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.62M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.63M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 59.67M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 56.60M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 82.44M | n/a | n/a | n/a |
About IN8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is IN8bio Inc's market cap?
IN8bio Inc's market capitalization is USD 11.53M.
What does IN8bio Inc do?
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.